← Back to Search

Integrating Electronic Patient Reported Biometric Measures (ePReBMs) From Wearable Devices in Respiratory Diseases

N/A
Waitlist Available
Led By Giovanni Ferrara, MD
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 month duration per participant
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a wearable device called ADAMM-RSMTM that measures heart rate, breathing rate, temperature, cough, and activity. It targets patients with serious lung diseases like IPF, CF, bronchiectasis, and TB. The device helps doctors monitor these patients' health by sending vital sign data to a secure database. The ADAMM-RSMTM device is an evolution of the ADAM device, which was developed for asthma monitoring in adolescents.

Eligible Conditions
  • Cystic Fibrosis
  • Bronchiectasis
  • PF-ILD
  • Tuberculosis
  • Lung Transplant

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 month duration per participant
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 month duration per participant for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Length of time wearing device (days)
Secondary study objectives
Prediction of respiratory exacerbations- Number of emergency room visits
Prediction of respiratory exacerbations- Number of hospital admissions

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: DeviceExperimental Treatment1 Intervention
All participants will wear the device to assist in determining the feasibility of wearing the device.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ADAMM- RSM Device
2021
N/A
~10

Find a Location

Who is running the clinical trial?

University of AlbertaLead Sponsor
941 Previous Clinical Trials
434,087 Total Patients Enrolled
1 Trials studying Cystic Fibrosis
213 Patients Enrolled for Cystic Fibrosis
Giovanni Ferrara, MDPrincipal InvestigatorUniversity of Alberta
1 Previous Clinical Trials
~2 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top